Novo Nordisk Inks Its Second Big Obesity Deal In A Week — And It's Not For A GLP-1
In This Article:
Novo Nordisk will pay Lexicon Pharmaceuticals up to $1 billion to license its experimental obesity treatment.
Oops, something went wrong
Novo Nordisk will pay Lexicon Pharmaceuticals up to $1 billion to license its experimental obesity treatment.